stock-detail (NVGN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Government Agency Selects RCCA to Participate in Innovative "Oncology Care Model” Initiative

6/20/2016 12:02 pm

(New Jersey Online) June 20, 2016 - Regional Cancer Care Associates LLC, or RCCA, is one of a select group of oncology organizations nationwide invited by the Centers for Medicare and Medicaid Services (CMS) to participate in the agency's Oncology Care Model, or OCM.

Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer

12/20/2013 12:00 pm

(Yahoo! Finance) Dec 20, 2013 - Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University.

Novogen, Yale Launch Venture to Develop Ovarian Cancer Drugs

11/6/2013 12:01 pm

(Genetic Engineering & Biotechnology News) Nov 6, 2013 - Novogen said today it is joining Yale University to launch a joint venture focused on fighting ovarian cancer by developing personalized approaches to chemotherapy.

Provectus Pharmaceuticals Presents Final Phase 2 Melanoma Data at ESMO 2012

10/2/2012 01:00 pm

(4-traders) Oct 2, 2012 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that final top-line data from its Phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the ESMO (European Society for Medical Oncology) 2012 Congress in Vienna, Austria on October 1, 2012.

Genomic Study of Rare Children's Cancer Yields Possible Prognostic Tool

8/9/2012 11:05 am

(Huntsman Cancer Institute) Aug 8, 2012 - A new study of the genetic makeup, or genome, of Ewing sarcoma, a rare cancer that strikes children, teenagers, and young adults, has produced multiple discoveries: a previously unknown sarcoma subtype, genetic factors related to long-term survival, and identification of a genetic change between the primary and metastatic stages of the disease that could lead to better, more targeted treatment.